CNKSR3 Inhibitors
CNKSR3 Inhibitors represent a class of chemical compounds designed to interact with and modulate the activity of the CNKSR3 protein. CNKSR3, also known as Connector enhancer of KSR-3, belongs to a group of proteins involved in cell signaling pathways, particularly those related to growth factors and receptor tyrosine kinases. While the precise functions and interactions of CNKSR3 are areas of ongoing research, it is acknowledged for its potential role in regulating cell signaling cascades. Inhibitors developed specifically for CNKSR3 are meticulously engineered to interfere with or regulate its activity, potentially influencing the cellular processes in which it plays a role.
The mechanism of action for CNKSR3 inhibitors primarily involves their ability to bind to the CNKSR3 protein, with a specific focus on its interaction sites or domains relevant to signal transduction. These interactions enable the inhibitors to disrupt or modulate the function of CNKSR3, potentially affecting cell signaling pathways and their downstream effects. Researchers rely on CNKSR3 inhibitors as vital tools to explore the intricacies of cell signaling processes and to decipher the specific roles played by CNKSR3 in mediating cellular responses to growth factors and receptor tyrosine kinases. By inhibiting CNKSR3, scientists aim to gain a deeper understanding of the molecular mechanisms governing cell signaling, ultimately contributing to the broader knowledge in the field of cellular biology and signal transduction.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a selective inhibitor of mitogen-activated protein kinase kinases (MEK1 and MEK2). It works by binding to and inhibiting MEK1/2, thus preventing the activation of mitogen-activated protein kinase (MAPK), also known as extracellular signal-related kinase (ERK). By inhibiting MEK1/2, Trametinib can indirectly influence the function of downstream scaffold proteins like CNKSR3, which play roles in mediating signals in the Ras/MAPK pathway. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib is another selective, non-ATP-competitive inhibitor of MEK1 and MEK2. Similar to Trametinib, Selumetinib works by inhibiting MEK1/2, preventing the downstream activation of ERK. This disrupts the signaling pathway leading to decreased cell proliferation. Given its similar mechanism of action to Trametinib, Selumetinib's inhibition of MEK1/2 can also indirectly affect the function of CNKSR3 within the Ras/MAPK pathway. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
Vemurafenib is a potent inhibitor of the mutated BRAFV600E kinase. The BRAFV600E mutation is common in various malignancies and results in constitutive activation of the BRAF kinase. Vemurafenib binds to and inhibits the activity of BRAFV600E, thereby halting downstream signaling, including MEK and ERK activation. By inhibiting mutated BRAF, Vemurafenib can potentially alter the signal flow through the Ras/MAPK pathway, thereby influencing scaffold proteins like CNKSR3. | ||||||
Dabrafenib | 1195765-45-7 | sc-364477 sc-364477A sc-364477B sc-364477C sc-364477D | 5 mg 25 mg 50 mg 100 mg 10 g | $141.00 $260.00 $278.00 $411.00 $12485.00 | 6 | |
Dabrafenib is another inhibitor targeting the mutated BRAFV600 kinase. Similar to Vemurafenib, Dabrafenib binds and inhibits BRAFV600, preventing its downstream signaling effects, including the activation of MEK and ERK. As with Vemurafenib, inhibiting mutated BRAF with Dabrafenib can influence the Ras/MAPK pathway's dynamics and potentially the function of CNKSR3. | ||||||